Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083551 · ClinicalTrials.gov registry record · Phase 3
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 668
- Enrollment target
NCT00083551 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 668 participants.
The verdict
NCT00083551, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 668 participants
- Enrollment target
Study Summary
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
Interventions
- DRUG Cisplatin
- DRUG Cytoxan
- DRUG BCNU
- DRUG Thalidomide
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 668 participants |
| Start Date | 1998-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083551
The ClinicalTrials.gov registry entry for NCT00083551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 668 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00083551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083551 about?
NCT00083551 is a clinical study titled "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy". This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
What is the current status of trial NCT00083551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 1998-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00083551?
The interventions under investigation include: Cisplatin (DRUG), Cytoxan (DRUG), BCNU (DRUG), Thalidomide (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00083551?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.